|
Conn Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
This study included 327 patients who had hypertension under plasma renin suppression and underwent captopril challenge test (CCT) between January 2007 and April 2019.CCT results were used to diagnose PA.
|
31665338 |
2020 |
|
Conn Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
Primary aldosteronism (PA) results from renin-independent production of aldosterone and is a common cause of hypertension.
|
31738186 |
2020 |
|
Conn Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
Renin-Angiotensin-Aldosterone System Triple-A Analysis for the Screening of Primary Aldosteronism.
|
31760886 |
2020 |
|
Conn Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
Patients with APA, compared with those with IHA and primary hypertension had a significantly (P < 0.001) lower serum potassium concentration and higher 24-h urinary aldosterone excretion and plasma aldosterone-to-renin ratio.
|
31157742 |
2019 |
|
Conn Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
(ii) Plasma aldosterone levels after a saline infusion test, plasma renin, and 24-hour urine steroid hormone metabolome and hemodynamic parameters were measured during an open-label study in 12 patients with PA, before and after 2 weeks of treatment with everolimus and after a 2-week washout.
|
31087053 |
2019 |
|
Conn Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
Primary hyperaldosteronism presents with low renin and aldosterone excess.
|
31655771 |
2019 |
|
Conn Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
Aldosterone to Renin Ratio as Screening Tool in Primary Aldosteronism.
|
30165708 |
2019 |
|
Conn Syndrome
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Mild primary aldosteronism (PA) followed by overt PA are possibly the most common forms of low renin hypertension: a single-center retrospective study.
|
31792441 |
2019 |
|
Conn Syndrome
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The strategy for diagnosis of primary aldosteronism (PA) in the hypertensive population includes firstly a screening step, based on the measurement of plasma aldosterone-to-renin ratio (ARR), a test which must have high sensitivity, and secondly a confirmatory step based on the demonstration of excessive aldosterone production independent of the renin-angiotensin-aldosterone system (RAAS) activity.
|
30475220 |
2019 |
|
Conn Syndrome
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
When age, sex, duration of hypertension, and BMI were matched between groups, snoring patients still showed significantly (P < 0.05) higher plasma renin activity, serum and urinary sodium, and lower ARR and eGFR than those in the PA-only group.
|
31089199 |
2019 |
|
Conn Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
Many antihypertensive medications modulate the renin-angiotensin-aldosterone system, possibly skewing the diagnosis and subtyping of primary aldosteronism (PA).
|
30239792 |
2019 |
|
Conn Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
To determine whether aldosterone, renin, or the plasma aldosterone/renin ratio (ARR) are associated with metabolic disorders and inflammatory/vascular biomarkers in a non-PA population.
|
30753255 |
2019 |
|
Conn Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
However, emerging evidence suggests that the prevalence of primary aldosteronism is much greater than previously recognized, and that milder and nonclassical forms of renin-independent aldosterone secretion that impart heightened cardiovascular risk may be common.
|
30124805 |
2018 |
|
Conn Syndrome
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
A plasma aldosterone concentration greater than 280 pmol/l after saline infusion was considered diagnostic for aldosteronism and the plasma renin activity was assessed to exclude patients with secondary aldosteronism from the final primary aldosteronism diagnosis.
|
29528872 |
2018 |
|
Conn Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
When compared with patients with essential hypertension, patients with PA treated with MR antagonists such that renin remained suppressed (as a proxy for insufficient MR blockade) had a significantly higher risk for incident AF; however, treatment of PA with MR antagonists to substantially increase renin (suggesting sufficient MR blockade), or with surgical adrenalectomy (to remove the source of aldosteronism), was associated with no significant difference in risk for developing AF.
|
30027227 |
2018 |
|
Conn Syndrome
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Over the last 20 years the clinical spectrum of low renin hypertension and primary aldosteronism has changed dramatically.
|
29629943 |
2018 |
|
Conn Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
The purpose of this pilot study was to objectively measure exercise response of the renin-angiotensin-aldosterone system and cardiopulmonary fitness changes after laparoscopic adrenalectomy (ADE) in patients with unilateral PA. We examined a total of 14 patients with confirmed PA before and after ADE, by means of spiroergometry and hormonal evaluation.
|
29303601 |
2018 |
|
Conn Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
The regulation of cortisol or aldosterone production when ACTH of pituitary origin or the renin-angiotensin systems are suppressed in primary adrenal Cushing's syndrome or in primary aldosteronism is exerted by diverse genetic and molecular mechanisms.
|
29678284 |
2018 |
|
Conn Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
Among patients with a body mass index ≥30 kg/m<sup>2</sup> , the aldosterone to renin ratio yielded lower case detection accuracy of PA. We conclude that obesity results in a nonlinear correlation with plasma aldosterone concentration, plasma renin activity, and aldosterone to renin ratio, which affects the accuracy of case detection for PA.
|
28612447 |
2017 |
|
Conn Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
Quantitative Value of Aldosterone-Renin Ratio for Detection of Aldosterone-Producing Adenoma: The Aldosterone-Renin Ratio for Primary Aldosteronism (AQUARR) Study.
|
28529209 |
2017 |
|
Conn Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
A/C = cortisol-corrected aldosterone concentration; ACE = angiotensin-converting enzyme; APA = aldosterone-producing adenoma; APCC = aldosterone-producing cell cluster; ARB = angiotensin receptor blocker; ARR = aldosterone-to-renin ratio; AVS = adrenal venous sampling; CT = computed tomography; ENaC = epithelial sodium channel; GRA = glucocorticoid remediable aldosteronism; IHA = idiopathic hyperaldosteronism; LI = lateralization ratio; MR = mineralocorticoid receptor; MRI = magnetic resonance imaging; PA = primary aldosteronism; PRA = plasma renin activity; SRA = surgical remediable aldosteronism.
|
28332881 |
2017 |
|
Conn Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
This suggests a link between the renin-angiotensin-aldosterone system and inflammatory processes in patients with primary aldosteronism and even in normotensive subjects.
|
28638984 |
2017 |
|
Conn Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
For those with a high aldosterone/low renin (primary aldosteronism) phenotype, aldosterone antagonists are best; for those with low renin/low aldosterone (a Liddle phenotype), amiloride is best.
|
28449833 |
2017 |
|
Conn Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
In participants without clinical PA, the inability to stimulate renin was associated with greater autonomous aldosterone secretion, impaired vascular function, and suggestive trends in potassium handling that indicate an extensive spectrum of unrecognized MR activation.
|
28323995 |
2017 |
|
Conn Syndrome
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In this article, the iMALDI assay is used for determining the peptide angiotensin I (Ang I) concentration in plasma, which is used clinically as readout of plasma renin activity for the screening of primary aldosteronism (PA).
|
28872133 |
2017 |